Skip to content

J. John Mann

2 papers in the library · 66 citations · publishing 2020-2023

Papers

Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression

JAMA Network Open August 12, 2020 Matthew S. Milak, Rain Rashid, Zhengchao Dong et al. 59 citations

A single subanesthetic dose of ketamine produces an antidepressant response in patients with major depressive disorder within hours. In this randomized clinical trial of 38 adults, higher ketamine doses and blood levels correlated with greater improvement on the Hamilton Depression Rating Scale 24 hours later. However, the brain's glutamate+glutamine (Glx) response to ketamine mediated this relationship: lower Glx responses predicted better antidepressant effects. GABA levels did not correlate with antidepressant benefit. Adverse effects were linked to blood levels only in men. The findings suggest that ketamine's antidepressant mechanism involves reducing Glx levels in the ventromedial prefrontal cortex.

Is psilocybin an effective antidepressant and what is its Mechanism of action?

Cell Reports Medicine January 1, 2023 J. John Mann 7 citations

A single 25 mg dose of psilocybin produces a short-term antidepressant effect in people with medication-resistant depression. Unanswered questions remain about whether drug blood levels can guide dosing, how the psychedelic experience relates to the antidepressant benefit, and whether psilocybin carries a risk of suicide.